SCHEMBL3370

SCHEMBL3370

C=CCOCC1CCCCC1=O

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
CA1 P00915 5/20 0.37
CA2 P00918 5/20 0.37
CA4 P22748 5/20 0.37
CA6 P23280 4/20 0.37
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
KMT2A Q03164 2/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NOS1 P29475 2/20 0.30
NOS2 P35228 2/20 0.30
NOS3 P29474 1/20 0.30
PTGS1 P23219 2/20 0.30
PTGS2 P35354 2/20 0.30
OPRK1 P41145 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3599 0.81 ALDH1A1 (0.40) ALDH1A1NOS1NOS2NOS3
SCHEMBL4989431 0.80 CA1 (0.38) ALDH1A1CA1CA2CA4CA6
SCHEMBL528992 0.76 NOS1 (0.46) ALDH1A1CA1CA2CA4CA6
SCHEMBL21297485 0.76 NOS1 (0.46) ALDH1A1CA1CA2CA4CA6
SCHEMBL11795168 0.74 ALDH1A1 (0.42) ALDH1A1CA1CA2CA4CA6
SCHEMBL7157465 0.74 NOS1 (0.44) ALDH1A1CA1CA2CA4CA6
SCHEMBL5064686 0.74 NOS1 (0.44) ALDH1A1CA1CA2CA4CA6
Ethylene SCHEMBL6509460 0.74 NOS1 (0.44) ALDH1A1CA1CA2CA4CA6
SCHEMBL10502755 0.74 NOS1 (0.44) ALDH1A1CA1CA2CA4CA6
SCHEMBL1134441 0.74 CA1 (0.41) ALDH1A1CA1CA2CA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829196-B2 TRPA1 antagonists MERCK SHARP & DOHME CORP. (US) 2014-09-09 US disclosed
US-8829196-B2 TRPA1 antagonists MERCK SHARP & DOHME CORP. (US) 2014-09-09 US disclosed
US-8829196-B2 TRPA1 antagonists MERCK SHARP & DOHME CORP. (US) 2014-09-09 US disclosed
EP-2485737-B1 NOVEL TRPA1 ANTAGONISTS MERCK SHARP & DOHME (US) 2014-06-25 EP disclosed
EP-2485737-B1 NOVEL TRPA1 ANTAGONISTS MERCK SHARP & DOHME (US) 2014-06-25 EP disclosed
EP-2485737-A1 NOVEL TRPA1 ANTAGONISTS Merck Sharp & Dohme Corp. (US) 2012-08-15 EP disclosed
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS SCHERING CORPORATION 2012-08-02 US disclosed
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS SCHERING CORPORATION 2012-08-02 US disclosed
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS SCHERING CORPORATION 2012-08-02 US disclosed
WO-2011043954-A1 NOVEL TRPA1 ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2011-04-14 WO disclosed
WO-2011043954-A1 NOVEL TRPA1 ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS TRPA1, TRPV1, TRPV2 ALDH1A1 3703/4885CA1 2397/4885CA2 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.